Open-label randomized study of individualized pharmacokinetically (PK)-guided dosing versus body surface area (BSA) dosing of paclitaxel (PTX) in advanced Non-Small Cell Lung Cancer (NSCLC)

Ann Oncol 2017 Sept; 28 (Suppl 5)

This randomized trial compared body-surface area (BSA) to pharmacokinetically-guided (PK) dosing. Compared to BSA dosing, targeting paclitaxel exposure significantly reduced toxicity without impacting efficacy

Start typing and press Enter to search